Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

September 30, September 30, 2009 2008(*) 2009 2008(*) Net revenue $21,425 $18,997 $68,347 $51,799 Cost of services 9,796 8,596 28,675 24,465 ----- ----- ------ ------ Gross profit 11,629 10,401 39,672 27,334 Operating expenses: Sales and marketing 4,194 2,634 13,116 7,664 General and administrative 6,030 3,377 17,074 13,289 Bad debt 4,214 4,107 9,483 7,734 Research and development 282 98 805 321 --- --- --- --- Total operating expenses 14,720 10,216 40,478 29,008 ------ ------ ------ ------ Income (loss) from operations (3,091) 185 (806) (1,674) ------ --- ---- ------ Interest expense, net 144 2,399 4,056 5,747 --- ----- ----- ----- Loss from continuing operations before income taxes (3,235) (2,214) (4,862) (7,421) Income tax benefit (expense) - - 599 (6) Income from discontinued operations, net of income taxes - - 901 - --- --- --- --- Net loss (3,235) (2,214) (3,362) (7,427) Series A preferred stock beneficial conversion feature - - (4,290) -
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... Kingdom -based Lab M Holdings, a developer, manufacturer ... Lab M was founded in 1971, ... testing and diagnostic products for the global food, water, ... into more than 70 countries worldwide, and has several ...
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... August 27, 2015 GlassesOff (OTCBB: GLSO), ... functions in the human vision system, announced today a partnership ... guard Chris Paul to develop a new mobile ... to improve their real-life on-court performance. Vision is ... it is shooting a ball or blocking a pass. The ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... 3 The Connecticut Technology,Council and UHY LLP is ... Connecticut. The list of winning companies, called the UHY ... revenue growth over the last four,years. Companies considered for ... of the public companies winning this year exceeding,$1Billion in ...
... MS, EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... U.S. pivotal phase III MAESTRO-03 trial of dirucotide ... a safety analysis,and recommended that the trial continue ...
... for Ap3ana, CTI,s ,personalized medicine, venture, SEATTLE, ... CTIC ) announced today that Christina A. Waters, ... Tyr Pharma and formerly Director of,Scientific Development at ... named President of CTI Europe. Based in Bresso, ...
Cached Biology Technology:Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners 2BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... promising on paper; things are,often very different in reality. ... are supposed to strip the "immortal" (able to,divide indefinitely) ... to block their function, preventing them to inhibit completely,the ... for something,else? Hell no! Look out for whats stopping ...
... Notch pathway ,is an important molecular signaling mechanism whose ... nearly a century since the,identification of a mutant strain ... lab in 1910. Later studies,revealed that the Notch gene ... the cell membrane and which is capable of,interacting with ...
Cached Biology News:GATA: a graphic alignment tool for comparative sequence analysis 2Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
... X-Ray System from KUBTEC is a dual capability ... three dimensional representation of the specimen under test. ... specimen X-ray images, the micro focus source also ... detail in standard 2D images. The 50 mm ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
Biology Products: